Hertz, D. L., Smith, K. L., Zong, Y., Gersch, C. L., Pesch, A. M., Lehman, J., . . . Stearns, V. (2021). Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer. Front Genet.
Chicago-tyylinen lähdeviittausHertz, Daniel L., et al. "Further Evidence That OPG Rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer." Front Genet 2021.
MLA-viiteHertz, Daniel L., et al. "Further Evidence That OPG Rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer." Front Genet 2021.
Varoitus: Nämä viitteet eivät aina ole täysin luotettavia.